Drug use
Alternative labels
Drug abuse
Report
Minimising the harms from methamphetamine
Harmful methamphetamine use has become a serious and intractable health issue in Aotearoa New Zealand over the past 20 years. The paper begins by providing an overview of how methamphetamine is used, by whom and why, how big the market is, what the harms are that it causes, and how it is currently regulated. The...
Article
‘Oh well, wine o’clock’: what midlife women told us about drinking – and why it’s so hard to stop
While alcohol reduction campaigns ask us to check our relationship with alcohol, emphasising the role it can play in causing violence and disease, this research has found many Australian women view alcohol in a different way. Many don’t see alcohol as only a bad thing and have complex reasons for their relationships with alcohol.
Report
National wastewater drug monitoring program: report 16
Report 16 of the National Wastewater Drug Monitoring Program covers around 56 per cent of the Australian population, which equates to about 13 million people. Fifty-six wastewater treatment plants across Australia participated in the December 2021 collection, which monitored the consumption of 12 substances.
Discussion paper
Needle and syringe programs in NSW: opportunities for innovation
This paper, produced by ACON, combines the expertise from staff who operate ACON’s needle and syringe programs with current research to provide seven policy recommendations that will innovate such programs.
Report
The firm and the FDA: McKinsey and Company’s conflicts of interest at the heart of the opioid epidemic
The Committee’s investigation has uncovered significant, years-long conflicts of interest at McKinsey, resulting from its work for the federal government at the same time it was advising opioid manufacturers, including providing advice on how to influence the regulatory decisions of the U.S. Food and Drug Administration (FDA), another McKinsey client.